Josep Darbà

PhD in Economic Analysis and Policy 1999, Universitat de Barcelona

darba@ub.eduPersonal webpage

Publications

Cost-effectiveness of dabigatran vs. rivaroxaban and vitamin k antagonists in elderly patients with nonvalvular atrial fibrillation in Spain

Schoenherr, N.; Soulard, S.; Crespo, C.; Ramírez, G.; Darba, J. (2016)

Value In Health, 19 (7), 651

Cost-effectiveness analysis of insulin degludec compared with insulin glargine in the management of type 1 and type 2 diabetes mellitus from the Spanish national health system perspective

Ramirez de Arellano, A.; Mezquita, P.; Darba, J. (2016)

Value In Health, 19 (7), 673

Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance

Darbà J, Ramírez G, Sicras A, García-Bujalance L (2016)

Patient Preference And Adherence, 9(10), 135-145

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Darbà J, Kaskens L, Sorio Vilela F, Lothgren M (2015)

Clinicoeconomics and Outcomes Research, 7, 105-117

Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study

Darba J,  Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A (2015)

Clinicoeconomics and Outcomes Research, 7, 163-171

Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in Spain

Darba J, Kaskens L, Lacey L (2015)

The European Journal of Health Economics, 16(8), 895-905

Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a spanish perspective

Darbà J, Kaskens L, Pérez C, Alvarez E, Navarro-Artieda R, Sicras-Mainar A (2014)

Advances in Therapy, 31(1), 1-29

Budget Impact Model of Ceplene® As Maintenance Therapy in Adult Patients with Acute Myeloid Leukemia in First Remission

Kaskens L, Gehenio D, Munzel U, Darba J (2014)

Value in Health, 17(7), A622

Qutenza® Estimated Costs Per Patient In Primary Versus Secondary Care. A Comparison Between Qutenza®, Pregabalin and Lidocaine for the Treatment of Peripheral Neuropathic Pain

Darba J, Kaskens L, Villa G (2014)

Value in Health, 7(17), A526

Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicemia

Darbà J, Hark M, Kaskens L, Wright C (2014)

Vaccine, 32(39), 5006-5012

A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

Darbà J, Kaskens L, Aranda P, Arango C, Bobes J, Carmena R, Rejas J (2013)

Annals Of Clinical Psychiatry, 25(1), 17-26

A Budget Impact Model for Novoseven for the Management of Bleeding Episodes in Patients with Haemophilia a Treated with Inhibitors

Kaskens L, Martial L, Montoro Ronsano J. B, Ramirez de Arellano A, Darba J (2013)

Value in Health, 16(7), A379

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Darba J, Kaskens L (2013)

Value in Health, 16(7), A623

Budget Impact Analysis of Fentanyl Buccal Tablet for the Treatment of Cancer Breaktrough Pain

Darba J, Kaskens L (2013)

Value in Health, 16(7), A400

Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain

Darbà J, Restovic G, Kaskens L, Agustín T (2012)

The Journal of Clinical Pharmacology, 52(4), 566-575

PIH35 Disability-Adjusted-Life-Years (DALYs) Loss in Postmenopausal Women with Osteoporosis

Darba J, Kaskens L, Perez-alvarez N, Palacios S, Neyro J. L, Rejas J (2012)

Value in Health, 15(7), A542

PGI6 A Budget Impact Analysis to Estimate the Economic Impact of Lactest for the Diagnosis of Hypolactasia in Spain

Darba J, Kaskens L, Ramírez de Arellano A (2012)

Value in Health, 15(7), A327

PGI15 Cost-Effectiveness Analysis of Lactest, a New Diagnostic Drug Test for Hypolactasia in Spain

Darba J, Kaskens L, de Arellano A. R (2012)

Value in Health, 15(7), A328

Patient preferences for osteoporosis in Spain: a discrete choice experiment

Darbà J, Restovic G, Kaskens L, Balbona M. A, Carbonell A, Cavero P, Jordana M, Prieto C, Molina A, Padró I (2011)

Osteoporosis International, 22(6), 1947-1954

Eficacia de los antipsicóticos de segunda generación en el tratamiento de los síntomas negativos de esquizofrenia: un metaanálisis de ensayos clínicos aleatorizados

Darbà J, Minoves A, Rojo E, Jimenez F, Rejas J (2011)

Revista de Psiquiatría y Salud Mental, 4(3), 126-143

Epidemiology and societal costs of gastroesophageal reflux disease and Barrett’s syndrome in Germany, Italy and Spain

Darbà J, Kaskens L, Plans P, Elizalde J. I, Coma M, Cuomo R, Santoiemma L, Geldmacher J (2011)

Expert review of pharmacoeconomics & outcomes research, 11(2), 225-232

Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials

Darbà J, Minoves A, Rojo E, Jimenez F, Rejas J (2011)

Revista de Psiquiatría y Salud Mental (English Edition), 4(3), 126-143

Assessment of potential measures in models of progression in Alzheimer disease

McLaughlin T, Buxton M, Mittendorf T, Rekedop W, Mucha L, Darbà J,  Jonsson L , Lacey L , Leibman C (2010)

Neurology, 75(14), 1256-1262

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

Verhoef T. I, Redekop W. K, Darba J, Geitona M, Hughes D. A, Siebert U, de Boer A, Maitland-van der Zee A. H, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos V. G, Pirmohamed M, Rosendaal F. R, van Schie R. M, Wadelius M, EU-PACT Group (2010)

Pharmacogenomics, 11(7), 989-1002